Search Brexit News

ad

NHS rejects ketamine for depression as psychiatrists accuse NICE of mental health discrimination

NHS rejects ketamine for depression as psychiatrists accuse NICE of mental health discrimination
Spravato (pictured), a nasal spray also known as esketamine, got the green light from the European Medicines Agency in December 2019 as a fast-acting treatment for depression sufferers.

* This article was originally published here

No comments:

Post a Comment